MCID: INF023
MIFTS: 50

Inflammatory Breast Carcinoma

Categories: Cancer diseases, Genetic diseases, Immune diseases, Rare diseases, Reproductive diseases, Skin diseases

Aliases & Classifications for Inflammatory Breast Carcinoma

MalaCards integrated aliases for Inflammatory Breast Carcinoma:

Name: Inflammatory Breast Carcinoma 12 15 17 71
Inflammatory Breast Cancer 74 52 54
Inflammatory Carcinoma of Breast 12
Inflammatory Breast Neoplasms 43
Breast Cancer, Inflammatory 52
Mastitis Carcinomatosa 12

Classifications:



External Ids:

Disease Ontology 12 DOID:6263
MeSH 43 D058922
NCIt 49 C4001
SNOMED-CT 67 254840009
UMLS 71 C0278601

Summaries for Inflammatory Breast Carcinoma

NIH Rare Diseases : 52 Inflammatory breast cancer (IBC) is a rare and aggressive type of breast cancer in which the cancer cells block the lymph vessels in the skin of the breast. This type of breast cancer is called "inflammatory" because the breast often looks swollen and red, or "inflamed." The skin may also look dimpled like the skin of an orange. IBC can be difficult to diagnose because there is no lump to feel or detect on a mammogram . It is crucial to identify IBC right away because early diagnosis and treatment can greatly improve the outcome. Patients are often given a combination of treatments, including chemotherapy , surgery, and radiation therapy . Approximately one-third of individuals diagnosed with IBC will become long-term survivors. Like other types of breast cancer, IBC can occur in men, but usually at an older age than in women. Some studies have shown an association between family history of breast cancer and IBC, but more studies are needed to draw firm conclusions.

MalaCards based summary : Inflammatory Breast Carcinoma, also known as inflammatory breast cancer, is related to linitis plastica and fallopian tube carcinoma, and has symptoms including edema, pain and peau d'orange. An important gene associated with Inflammatory Breast Carcinoma is CDH1 (Cadherin 1), and among its related pathways/superpathways are ERK Signaling and Nanog in Mammalian ESC Pluripotency. The drugs leucovorin and Methotrexate have been mentioned in the context of this disorder. Affiliated tissues include breast, skin and lymph node, and related phenotypes are cardiovascular system and cellular

Disease Ontology : 12 A breast adenocarcinoma that is characterized by the clinical appearance of inflammation, with edema and redness of the breast due to pathologic plugging of the dermal lymphatics of the breast with tumor emboli.

Wikipedia : 74 Inflammatory breast cancer (IBC) is one of the most aggressive forms of breast cancer. It can occur at... more...

Related Diseases for Inflammatory Breast Carcinoma

Diseases in the Breast Cancer family:

Inflammatory Breast Carcinoma Sporadic Breast Cancer
Breast Carcinoma in Situ

Diseases related to Inflammatory Breast Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 308)
# Related Disease Score Top Affiliating Genes
1 linitis plastica 29.6 PGR ERBB2 CDH1
2 fallopian tube carcinoma 29.5 PGR ESR1 ERBB2
3 gynecomastia 29.5 PGR ESR1 ERBB2
4 lymphangioma 29.3 PROX1 LYVE1 EGFR CDH1
5 female breast cancer 29.2 PGR ESR1 ERBB2 EGFR
6 exanthem 29.2 ERBB2 EGFR CSF3
7 suppression of tumorigenicity 12 29.2 ESR1 ERBB2 EGFR CDH1
8 breast disease 29.1 RHOC PGR ESR1 ERBB2
9 diarrhea 28.8 ERBB2 EGFR CSF3 CDH1
10 adenocarcinoma 28.6 VEGFD ERBB2 EGFR CDH1
11 in situ carcinoma 28.6 PGR ESR1 ERBB2 EGFR CDH1
12 ovary adenocarcinoma 28.6 PGR ESR1 ERBB2 EGFR CDH1
13 ductal carcinoma in situ 28.6 PGR ESR1 ERBB2 EGFR CDH1
14 lung cancer susceptibility 3 28.3 VEGFD ESR1 ERBB2 EGFR CDH1
15 glioblastoma multiforme 28.1 RHOC ESR1 ERBB2 EGFR CSF3 CDH1
16 breast ductal carcinoma 27.9 VEGFD PGR ESR1 ERBB2 EGFR CDH1
17 breast cancer 27.8 VEGFD RHOC PGR LYVE1 ESR1 ERBB2
18 ovarian cancer 27.1 VEGFD PGR LYVE1 ESR1 ERBB2 EGFR
19 esophageal cancer 27.0 VEGFD ERBB2 EGFR CSF3 CDH1
20 acquired hemangioma 10.4 PROX1 LYVE1
21 lymphangiosarcoma 10.3 PROX1 LYVE1
22 capillary lymphangioma 10.3 PROX1 LYVE1
23 breast cystic hypersecretory carcinoma 10.3 ERBB2 CDH1
24 neutropenia 10.3
25 mastitis 10.3
26 bartholin's gland adenoid cystic carcinoma 10.3 PGR ESR1
27 chronic tympanitis 10.3 PGR ESR1
28 bartholin's gland adenoma 10.3 PGR ESR1
29 granulomatous endometritis 10.3 PGR ESR1
30 bartholin's gland benign neoplasm 10.3 PGR ESR1
31 vestibular gland benign neoplasm 10.3 PGR ESR1
32 uterine corpus adenosarcoma 10.3 PGR ESR1
33 vaginal glandular tumor 10.3 PGR ESR1
34 lung leiomyoma 10.2 PGR ESR1
35 vulvar syringoma 10.2 PGR ESR1
36 trigonitis 10.2 PGR ESR1
37 cervical clear cell adenocarcinoma 10.2 PGR ESR1
38 adult type testicular granulosa cell tumor 10.2 PGR ESR1
39 ovarian seromucinous carcinoma 10.2 PGR ESR1
40 liver leiomyoma 10.2 PGR ESR1
41 intravenous leiomyomatosis 10.2 PGR ESR1
42 gastric diffuse adenocarcinoma 10.2 ERBB2 CDH1
43 mammographic density 10.2 PGR ESR1
44 bizarre leiomyoma 10.2 PGR ESR1
45 esophageal adenosquamous carcinoma 10.2 ERBB2 CDH1
46 vulvar leiomyoma 10.2 PGR ESR1
47 progesterone resistance 10.2 PGR ESR1
48 urethral benign neoplasm 10.2 PGR ESR1
49 esophagus verrucous carcinoma 10.2 EGFR CDH1
50 mucositis 10.2

Graphical network of the top 20 diseases related to Inflammatory Breast Carcinoma:



Diseases related to Inflammatory Breast Carcinoma

Symptoms & Phenotypes for Inflammatory Breast Carcinoma

UMLS symptoms related to Inflammatory Breast Carcinoma:


edema, pain, peau d'orange

MGI Mouse Phenotypes related to Inflammatory Breast Carcinoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.01 CDH1 EGFR ERBB2 ESR1 LYVE1 PGR
2 cellular MP:0005384 9.97 CDH1 EGFR ERBB2 ESR1 LYVE1 PGR
3 immune system MP:0005387 9.91 CDH1 CSF3 EGFR ESR1 LYVE1 PGR
4 endocrine/exocrine gland MP:0005379 9.87 CCN6 CDH1 EGFR ERBB2 ESR1 PGR
5 integument MP:0010771 9.7 CCN6 CDH1 CSF3 EGFR ERBB2 ESR1
6 neoplasm MP:0002006 9.56 CCN6 CDH1 EGFR ERBB2 ESR1 PGR
7 normal MP:0002873 9.23 CCN6 CDH1 EGFR ERBB2 ESR1 PGR

Drugs & Therapeutics for Inflammatory Breast Carcinoma

Drugs for Inflammatory Breast Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 163)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
leucovorin Approved Phase 3 58-05-9 6006 143
2
Methotrexate Approved Phase 3 59-05-2, 1959-05-2 126941
3
Epirubicin Approved Phase 3 56420-45-2 41867
4
Fluorouracil Approved Phase 3 51-21-8 3385
5
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
6
Thiotepa Approved, Investigational Phase 3 52-24-4 5453
7
Lenograstim Approved, Investigational Phase 3 135968-09-1
8
Melphalan Approved Phase 3 148-82-3 460612 4053
9
Fosaprepitant Approved Phase 3 172673-20-0 219090
10
Palonosetron Approved, Investigational Phase 3 135729-56-5, 119904-90-4 148211
11
Aprepitant Approved, Investigational Phase 3 170729-80-3 6918365 151165
12
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
13
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
14
Prochlorperazine Approved, Vet_approved Phase 3 58-38-8, 1984-02-6 4917
15
Sargramostim Approved, Investigational Phase 3 83869-56-1, 123774-72-1
16
Busulfan Approved, Investigational Phase 3 55-98-1 2478
17
Cisplatin Approved Phase 2, Phase 3 15663-27-1 2767 441203 84093
18
Goserelin Approved Phase 2, Phase 3 65807-02-5 5311128 47725
19
Letrozole Approved, Investigational Phase 2, Phase 3 112809-51-5 3902
20
Leuprolide Approved, Investigational Phase 2, Phase 3 53714-56-0 657181 3911
21
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
22
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
23
Sodium citrate Approved, Investigational Phase 3 68-04-2
24
Tamoxifen Approved Phase 3 10540-29-1 2733526
25
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
26
Trastuzumab Approved, Investigational Phase 3 180288-69-1 9903
27
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
28
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
29 Molgramostim Investigational Phase 3 99283-10-0
30 Vitamin B Complex Phase 3
31 Folic Acid Antagonists Phase 3
32 Folate Phase 3
33 Dermatologic Agents Phase 3
34 Vitamin B9 Phase 3
35 taxane Phase 3
36 Dopamine Agents Phase 3
37 Neurotransmitter Agents Phase 3
38 Gastrointestinal Agents Phase 3
39 Dopamine Antagonists Phase 3
40 neurokinin A Phase 3
41 Antiemetics Phase 3
42 Psychotropic Drugs Phase 3
43 Antipsychotic Agents Phase 3
44
Substance P Phase 3 33507-63-0 44359816
45 Serotonin 5-HT3 Receptor Antagonists Phase 3
46 glucocorticoids Phase 3
47 Anti-Inflammatory Agents Phase 3
48 Aromatase Inhibitors Phase 2, Phase 3
49 Antibiotics, Antitubercular Phase 3
50 Albumin-Bound Paclitaxel Phase 3

Interventional clinical trials:

(show top 50) (show all 130)
# Name Status NCT ID Phase Drugs
1 A Randomised Comparative Trial of Highly Intensive Chemotherapy With Stem Cell Support vs. Relatively Intensive Chemotherapy (CMF 8 Cycles) in Breast Cancer Patients Node Positive Surgery, Having Received Primary Medical Therapy With an Anthracycline Regimen Unknown status NCT00003680 Phase 3 CMF regimen;cyclophosphamide;fluorouracil;methotrexate;tamoxifen citrate;thiotepa
2 A Randomized Phase III Trial Comparing Nanoparticle-based Paclitaxel With Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Patients With Early Breast Cancer (GeparSepto) Unknown status NCT01583426 Phase 3 nab-Paclitaxel;Paclitaxel
3 A Randomised Comparative Trial of Adriamycin + Taxotere vs. Adriamycin + Cyclophosphamide as Primary Medical Therapy for Patients With Potentially Operable Breast Cancer Greater Than or Equal to 3 cm Diameter, Locally Advanced, or Inflammatory Disease Unknown status NCT00003679 Phase 3 cyclophosphamide;docetaxel;doxorubicin hydrochloride;tamoxifen citrate
4 ARTemis - Avastin Randomized Trial With Neo-Adjuvant Chemotherapy for Patients With Early Breast Cancer Unknown status NCT01093235 Phase 3 cyclophosphamide;docetaxel;epirubicin hydrochloride;fluorouracil
5 Combination Capecitabine (Xeloda) and ABI-007 (Abraxane, Nanoparticle Albumin-Bound Paclitaxel) Chemotherapy as Neoadjuvant Treatment of Locally Advanced, Operable Breast Cancer Unknown status NCT00397761 Phase 2, Phase 3 capecitabine;paclitaxel albumin-stabilized nanoparticle formulation
6 Phase III Trial Assessing the Interest of a Maintenance Chemotherapy Combining Docetaxel (Taxotere) 5-FU After Induction Treatment by Aintensive Chemotherapy for Inflammatory Breast Cancers Completed NCT02324088 Phase 3 Docetaxel;Cyclophosphamide;Epirubicin
7 A Randomized Phase II Trial Investigating the Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer Completed NCT01426880 Phase 2, Phase 3 Carboplatin;background treatment
8 First Prospective Intergroup Translational Research Trial Assessing the Potential Predictive Value of p53 Using a Functional Assay in Yeast in Patients With Locally Advanced/Inflammatory or Large Operable Breast Cancer Prospectively Randomised to a Taxane Versus a Non Taxane Regimen Completed NCT00017095 Phase 3 cyclophosphamide;docetaxel;epirubicin hydrochloride;fluorouracil
9 A Comparative Randomized Study of Standard Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel Vs. Weekly Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF Followed by Weekly Paclitaxel As Neoadjuvant Therapy For Inflammatory and Locally Advanced Breast Cancer Completed NCT00016406 Phase 3 cyclophosphamide;doxorubicin;paclitaxel
10 Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial Completed NCT00475085 Phase 3 aprepitant;dexamethasone;granisetron hydrochloride;palonosetron hydrochloride;prochlorperazine;placebo
11 A Randomized Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto) Completed NCT02125344 Phase 3 non-pegylated liposomal doxorubicin;Carboplatin;Paclitaxel;Epirubicin;Cyclophosphamide;Pertuzumab;Trastuzumab;Ferric carboxymaltose
12 A Phase III Study of High-Dose Chemotherapy Using Busulfan, Melphalan and Thiotepa Versus Cyclophosphamide,Thiotepa, Carboplatin Followed by Autologous Stem Cell Transplantation in Patients With High-Risk Primary Stage II or III (Non-Inflammatory) Breast Cancer Completed NCT00003972 Phase 3 busulfan;carboplatin;cyclophosphamide;melphalan;paclitaxel;tamoxifen citrate;thiotepa
13 Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer Completed NCT00038402 Phase 3 Herceptin;Taxol;Fluorouracil;Cytoxan;Epirubicin
14 A Randomized Phase III Study Exploring the Efficacy of Capecitabine Given Concomitantly or in Sequence to EC-Doc With or Without Trastuzumab as Neoadjuvant Treatment of Primary Breast Cancer Completed NCT00288002 Phase 3 capecitabine;cyclophosphamide;docetaxel;epirubicin hydrochloride
15 A Randomized Phase III Trial of Comparing Combination Administration of Paclitaxel and Cisplatin Versus CEF as Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy Recruiting NCT02879513 Phase 3 Paclitaxel;Cisplatin;Epirubicin;Cyclophosphamide;5-fluoruracil
16 A Prospective, Randomized, Open-label Comparison of Preoperative Weekly Paclitaxel and Cisplatin With or Without Endocrine Therapy in Patients With Operable Hormone Receptor Positive and Triple Negative Locally Advanced Breast Cancer Active, not recruiting NCT02221999 Phase 2, Phase 3 Paclitaxel;Cisplatin;Gonadotropin-releasing hormone agonist;Letrozole
17 Conservative Local Treatment Versus Mastectomy After Induction Chemotherapy In Locally Advanced Breast Cancer: A Randomized Phase III Study Terminated NCT00028704 Phase 3
18 A 2X2X2 Factorial Randomized Phase III Trial Of Multimodality Therapy Comparing 4 Cycles Of Doxorubicin And Cyclophosphamide With Or Without Dexrazoxane (AC+/-Z) Followed By 12 Weeks Of Weekly Paclitaxel With Or Without Trastuzumab (T+/-H) Followed By Local Therapy Followed By 40 Weeks Of Weekly Trastuzumab Or None In Women With HER-2+ STAGE IIIA, IIIB OR REGIONAL STAGE IV BREAST CANCER Terminated NCT00016276 Phase 3 dexrazoxane hydrochloride;doxorubicin hydrochloride;cyclophosphamide;paclitaxel;tamoxifen citrate
19 PROMIX - Preoperative Treatment of Breast Cancer With a Combination of Epirubicin, Docetaxel and Bevacizumab. A Translational Trial on Molecular Markers and Functional Imaging to Predict Response Early. A Phase 2 Study. Unknown status NCT00957125 Phase 2 Epirubicin;Docetaxel;Bevacizumab
20 PHASE I/II TRIAL OF THE ADDITION OF TAXOL TO HIGH DOSE CARBOPLATIN AND CYCLOPHOSPHAMIDE WITH AUTOLOGOUS PERIPHERAL BLOOD PROGENITOR CELL SUPPORT IN PATIENTS WITH HIGH RISK STAGE II AND III BREAST CANCER Unknown status NCT00002627 Phase 1, Phase 2 carboplatin;cyclophosphamide;mesna;paclitaxel
21 Phase II Neoadjuvant Trial of Docetaxel (Taxotere), Carboplatin, and Capecitabine (Xeloda) in the Treatment of Early Stage Locally Advanced and Inflammatory Breast Cancer Unknown status NCT00251329 Phase 2 neoadjuvant chemotherapy
22 Evaluation of Response Rate to Pre-Operative Docetaxel + Herceptin Study Part A and Docetaxel Study Part B in Locally Advanced Breast Cancer Patients, Stratified by HER2-Status Trial - PHASE II [(Herceptin Docetaxel Neoadjuvant) HEDON] Unknown status NCT00398489 Phase 2 anastrozole;cyclophosphamide;docetaxel;epirubicin hydrochloride;goserelin acetate;tamoxifen citrate
23 "Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer" Unknown status NCT01641406 Phase 2 Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab;Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab;Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab
24 Adjuvant Trastuzumab vs Observation in Locally Advanced Breast Cancer Treated With Neoadjuvant Trastuzumab Unknown status NCT00533936 Phase 2 cyclophosphamide;doxorubicin hydrochloride;fluorouracil;paclitaxel
25 Phase II Trial of Dose Dense Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer Completed NCT00193206 Phase 2 Gemcitabine;Epirubicin;Albumin-bound Paclitaxel
26 A Pilot Study to Evaluate Angiogenesis After Treatment With Bevacizumab (Anti-VEGF Humanized Monoclonal Antibody) in Previously Untreated Patients With Inflammatory Breast Cancer or Locally Advanced Breast Cancer Completed NCT00016549 Phase 2
27 A Randomized, Multicenter, Phase III Study Comparing the Combination of Pazopanib and Lapatinib Versus Lapatinib Monotherapy in Patients With ErbB2 Over-expressing Inflammatory Breast Cancer Completed NCT00558103 Phase 2 lapatinib;Pazopanib
28 A Phase I/II Study Of Increasing Doses Of Epirubicin And Docetaxel Plus Pegfilgrastim For Locally Advanced Or Inflammatory Breast Cancer Completed NCT00066443 Phase 1, Phase 2 docetaxel;epirubicin hydrochloride
29 Phase II Trial of Induction Chemotherapy With Weekly Gemcitabine, Epirubicin, Docetaxel as Primary Treatment of Locally Advanced or Inflammatory Breast Cancer Patients Completed NCT00193050 Phase 2 Gemcitabine;Epirubicin;Docetaxel
30 An Open Label, Phase II Trial of Afatinib With or Without Vinorelbine for the Treatment of HER2-overexpressing Inflammatory Breast Cancer Completed NCT01325428 Phase 2 Afatinib once daily (OD);Vinorelbine Weekly
31 A Phase II Study to Evaluate the Efficacy, Safety and Pharmacodynamics of Lapatinib in Patients With Relapsed or Refractory Inflammatory Breast Cancer Completed NCT00105950 Phase 2 lapatinib
32 A Phase II, Multi Centre Study of BGB324 in Combination With Pembrolizumab in Patients With Previously Treated, Locally Advanced and Unresectable or Metastatic Triple Negative Breast Cancer (TNBC) or Triple Negative Inflammatory Breast Cancer (TN-IBC) Completed NCT03184558 Phase 2 Bemcentinib; pembrolizumab
33 A Phase II Study to Evaluate the Efficacy, Safety, and Pharmacodynamics of Lapatinib in Combination With Paclitaxel as Neoadjuvant Therapy in Patients With Newly Diagnosed Inflammatory Breast Cancer Completed NCT00111787 Phase 2 Lapatinib;Paclitaxel
34 Phase I/II Study of TLC D-99 Plus Herceptin as First or Second Line Therapy for Patients With Locally Advanced Inflammatory or Metastatic Breast Cancer Completed NCT00004925 Phase 1, Phase 2 pegylated liposomal doxorubicin hydrochloride
35 A Phase II Trial of Pre-Operative Taxol and Carboplatin in Women With Newly Diagnosed Locally Advanced Operable Breast Cancer Completed NCT00096343 Phase 2 carboplatin;paclitaxel
36 Phase II Study of Neoadjuvant Treatment With NOV-002 in Combination With Doxorubicin and Cyclophosphamide Followed by Docetaxel in Patients With Stages IIB-IIIC Breast Cancer Completed NCT00499122 Phase 2 Cyclophosphamide;Docetaxel;Doxorubicin;NOV 002
37 Phase II Study Evaluating the Efficacy and Tolerance of Bevacizumab (Avastin) in HER2- Inflammatory Breast Cancer Completed NCT00820547 Phase 2 cyclophosphamide;docetaxel;epirubicin hydrochloride;fluorouracil
38 A Phase II Study of TKI258 (Dovitinib Lactate) as Salvage Therapy in Patients With Stage IV HER2-negative Inflammatory Breast Cancer (IBC) and Local or Distant Relapse Completed NCT01262027 Phase 2 Dovitinib
39 A Phase II Study Evaluating the Safety and Efficacy of Sunitinib Maleate in Combination With Weekly Paclitaxel Followed by Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF as Neoadjuvant Chemotherapy for Locally Advanced or Inflammatory Breast Cancer Completed NCT00513695 Phase 2 sunitinib malate;paclitaxel;doxorubicin hydrochloride;cyclophosphamide
40 Phase Ib/II Neoadjuvant Trial of the Farnesyltransferase Inhibitor, R115777 With Docetaxel and Capecitabine for Patients With Stage IIIA or IIIB Breast Cancer Completed NCT00070252 Phase 1, Phase 2 Capecitabine;Docetaxel;Tipifarnib
41 A Phase II Neoadjuvant Trial of Sequential Doxorubicin and Docetaxel for the Treatment of Stage III Breast Cancer Measuring STAT Activation as a Predictor of Response to Therapy Completed NCT00005800 Phase 2 Docetaxel;Doxorubicin
42 A Phase II Study of Cyclophosphamide, Thiotepa, and Carboplatin (CTC) as a Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation in Patients With Breast Cancer Completed NCT00005798 Phase 2 Carboplatin;Cyclophosphamide;Thiotepa
43 Pilot Study of Epirubicin and Cyclophosphamide Followed by Paclitaxel at 10-11 Days Interval for Women With Early Breast Carcinoma Completed NCT00072319 Phase 2 cyclophosphamide;epirubicin hydrochloride;paclitaxel
44 Phase II Trial of Herceptin Concurrent With External Beam Radiation Following Neoadjuvant Chemotherapy for the Treatment of HER2 Over-Expressing Breast Cancer Completed NCT00943410 Phase 2 Herceptin
45 A Phase I-II Study of R115777 (ZARNESTRA) Plus Doxorubicin and Cyclophosphamide in Patients With Locally Advanced Breast Cancer and Metastatic Breast Cancer Completed NCT00049114 Phase 2 doxorubicin hydrochloride;cyclophosphamide;tipifarnib
46 Nonrandomized Ph II Study of Multimodality Therapy for Stg IIB, IIIA/B, or Stg IV Breast Cancer w/4 Cycles of Adriamycin and Cytoxan (AC),Followed by 12 Weeks of Paclitaxel w/ or w/o Herceptin Followed by Local Therapy Followed by Wkly Herceptin or no Additional Therapy Completed NCT00006110 Phase 2 cyclophosphamide;doxorubicin hydrochloride;paclitaxel
47 Phase II Study of Tandem Cycle Dose-Intense Chemotherapy of Melphalan and Carboplatin, Thiotepa and Cyclophosphamide (STMP V) ± Trastuzumab Followed by Helical Tomotherapy or Local Regional Radiation Therapy for Stage IV Metastatic and Stage IIIB/C Breast Cancer Completed NCT00182793 Phase 2 carboplatin;cyclophosphamide;melphalan;thiotepa
48 A Phase II Clinical Trial of Epirubicin Plus Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and Bevacizumab Given as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or Given as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer Completed NCT00464646 Phase 2 Epirubicin;Cyclophosphamide;Docetaxel;Trastuzumab;Bevacizumab
49 Phase 2 Study of Weekly Paclitaxel in Combination With Cisplatin as Neoadjuvant Therapy for Locally Advanced Breast Cancer Patients Completed NCT02199418 Phase 2 Paclitaxel;Cisplatin
50 A Phase II Study of Neoadjuvant Treatment With Pegylated Liposomal Doxorubicin (Caelyx) and Cyclophosphamide +/- Trastuzumab Followed by Docetaxel in Patients With Locally Advanced Breast Cancer Completed NCT01206881 Phase 2 pegylated liposomal doxorubicin

Search NIH Clinical Center for Inflammatory Breast Carcinoma

Cochrane evidence based reviews: inflammatory breast neoplasms

Genetic Tests for Inflammatory Breast Carcinoma

Anatomical Context for Inflammatory Breast Carcinoma

MalaCards organs/tissues related to Inflammatory Breast Carcinoma:

40
Breast, Skin, Lymph Node, Endothelial, Brain, Bone, Prostate

Publications for Inflammatory Breast Carcinoma

Articles related to Inflammatory Breast Carcinoma:

(show top 50) (show all 1361)
# Title Authors PMID Year
1
X-linked inhibitor of apoptosis protein inhibits apoptosis in inflammatory breast cancer cells with acquired resistance to an ErbB1/2 tyrosine kinase inhibitor. 61 54
20406946 2010
2
Expression of WISP3 and RhoC genes at mRNA and protein levels in inflammatory and noninflammatory breast cancer in Tunisian patients. 61 54
20014943 2010
3
Blockade of CCN6 (WISP3) activates growth factor-independent survival and resistance to anoikis in human mammary epithelial cells. 54 61
20395207 2010
4
Biology and management of inflammatory breast cancer. 54 61
20131997 2010
5
Molecular plasticity of E-cadherin and sialyl lewis x expression, in two comparative models of mammary tumorigenesis. 61 54
19675678 2009
6
Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study. 61 54
19394894 2009
7
Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California Cancer Registry. 61 54
19228416 2009
8
Role of endocrine responsiveness and HER2/neu overexpression in inflammatory breast cancer treated with multimodality preoperative therapy. 61 54
18821931 2008
9
The predictive value of PgR and HER-2 for response to primary systemic chemotherapy in inflammatory breast cancer. 54 61
18704635 2008
10
Inhibition of CCN6 (Wnt-1-induced signaling protein 3) down-regulates E-cadherin in the breast epithelium through induction of snail and ZEB1. 61 54
18321996 2008
11
Plasma MMP1 and MMP8 expression in breast cancer: protective role of MMP8 against lymph node metastasis. 54 61
18366705 2008
12
Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. 54 61
18212337 2008
13
Trastuzumab signaling in ErbB2-overexpressing inflammatory breast cancer correlates with X-linked inhibitor of apoptosis protein expression. 54 61
18202008 2008
14
NF-kappaB activation in inflammatory breast cancer is associated with oestrogen receptor downregulation, secondary to EGFR and/or ErbB2 overexpression and MAPK hyperactivation. 54 61
17700572 2007
15
Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer. 54 61
17351259 2007
16
Vascular endothelial growth factor-C in patients with breast cancer. 61 54
17591368 2007
17
Dominant-negative E-cadherin inhibits the invasiveness of inflammatory breast cancer cells in vitro. 61 54
16932944 2007
18
CCN6 (WISP3) as a new regulator of the epithelial phenotype in breast cancer. 61 54
17587813 2007
19
High prevalence of HER-2/neu and p53 overexpression in inflammatory breast cancer. 54 61
16755113 2006
20
[Biological significance of E-cadherin in an inflammatory breast carcinoma cell line]. 61 54
16737610 2006
21
RhoC-GTPase is a novel tissue biomarker associated with biologically aggressive carcinomas of the breast. 61 54
16187229 2005
22
Occult inflammatory breast cancer: review of clinical, mammographic, US and pathologic signs. 61 54
15883516 2005
23
Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification. 61 54
15585631 2004
24
High incidence of HER-2 positivity in inflammatory breast cancer. 61 54
15019688 2004
25
WISP3 (CCN6) is a secreted tumor-suppressor protein that modulates IGF signaling in inflammatory breast cancer. 54 61
15140407 2004
26
Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M. D. Anderson Cancer Center experience. 54 61
15023242 2004
27
WISP3 and RhoC guanosine triphosphatase cooperate in the development of inflammatory breast cancer. 54 61
14696649 2004
28
Commentary re: N. J. McCarthy et al., microvessel density, expression of estrogen receptor alpha, MIB-1, p53 and c-erbB-2 in inflammatory breast cancer. Clin. Cancer Res., 8: 3857-3862, 2002. 61 54
14506176 2003
29
Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong E-cadherin expression. 61 54
12618881 2003
30
Microvessel density, expression of estrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast cancer. 54 61
12473600 2002
31
Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer. 61 54
12386822 2002
32
Reversion of RhoC GTPase-induced inflammatory breast cancer phenotype by treatment with a farnesyl transferase inhibitor. 54 61
12479217 2002
33
[Establishment and characterization of human inflammatory breast carcinoma neoplasm transplantation in nude mice]. 54 61
16201199 2001
34
Persistent E-cadherin expression in inflammatory breast cancer. 61 54
11353057 2001
35
High-dose sequential chemotherapy with recombinant granulocyte colony-stimulating factor and repeated stem-cell support for inflammatory breast cancer patients: does impact on quality of life jeopardize feasibility and acceptability of treatment? 54 61
10673516 2000
36
A novel human xenograft model of inflammatory breast cancer. 54 61
10537277 1999
37
A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. 61 54
10499627 1999
38
Expression of vascular endothelial growth factor (VEGF) family members in breast cancer. 61 54
10551327 1999
39
Metaplastic breast carcinoma: a cytohistologic and clinical study of 10 cases. 61 54
8732652 1996
40
[18F]FDG PET/CT in the staging of inflammatory breast cancer: A systematic review. 61
32416347 2020
41
Biological subtype, treatment response and outcomes in inflammatory breast cancer using data from the National Cancer Database. 61
32057107 2020
42
Better survival after surgery of the primary tumor in stage IV inflammatory breast cancer. 61
32561098 2020
43
Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2-Positive Inflammatory and Noninflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy with or without Trastuzumab. 61
32003919 2020
44
IL-8 and MCP-1/CCL2 regulate proteolytic activity in triple negative inflammatory breast cancer a mechanism that might be modulated by Src and Erk1/2. 61
32512068 2020
45
Discrepancy between FDG-PET/CT and contrast-enhanced CT in the staging of patients with inflammatory breast cancer: implications for treatment planning. 61
32318957 2020
46
An inflammatory imposter: Three cases of Mullerian carcinoma appearing as inflammatory breast cancer. 61
31960546 2020
47
The CD151-midkine pathway regulates the immune microenvironment in inflammatory breast cancer. 61
32129471 2020
48
Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC. 61
32423453 2020
49
A rare case of gastric cancer with bilateral breast metastasis during pregnancy. 61
32448025 2020
50
Epigenetics in Inflammatory Breast Cancer: Biological Features and Therapeutic Perspectives. 61
32397183 2020

Variations for Inflammatory Breast Carcinoma

Expression for Inflammatory Breast Carcinoma

Search GEO for disease gene expression data for Inflammatory Breast Carcinoma.

Pathways for Inflammatory Breast Carcinoma

Pathways related to Inflammatory Breast Carcinoma according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.55 VEGFD RHOC ESR1 ERBB2 EGFR CSF3
2
Show member pathways
13.04 VEGFD ESR1 ERBB2 EGFR CDH1
3
Show member pathways
13.02 VEGFD RHOC ERBB2 EGFR CSF3 CDH1
4
Show member pathways
12.71 RHOC ERBB2 EGFR CDH1
5 12.53 VEGFD ESR1 ERBB2 EGFR CDH1
6
Show member pathways
12.42 ESR1 ERBB2 EGFR CDH1
7
Show member pathways
12.41 VEGFD PGR ESR1 EGFR
8
Show member pathways
12.39 PGR ESR1 ERBB2 EGFR CDH1
9
Show member pathways
12.06 VEGFD RHOC ERBB2 EGFR CDH1
10 11.93 ESR1 EGFR CDH1
11
Show member pathways
11.91 RHOC ERBB2 EGFR CDH1
12 11.72 RHOC EGFR CDH1
13
Show member pathways
11.64 ESR1 ERBB2 EGFR
14 11.5 ERBB2 EGFR CDH1
15 11.46 ERBB2 EGFR CDH1
16
Show member pathways
11.29 PGR ESR1 ERBB2 EGFR
17 11.06 ERBB2 EGFR
18 10.83 EGFR CDH1
19 10.82 ERBB2 EGFR CDH1
20 10 VEGFD RHOC ERBB2 EGFR CSF3 CDH1

GO Terms for Inflammatory Breast Carcinoma

Biological processes related to Inflammatory Breast Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 multicellular organism development GO:0007275 9.73 VEGFD PROX1 ERBB2 EGFR CSF3 CDH1
2 positive regulation of protein phosphorylation GO:0001934 9.5 VEGFD ERBB2 EGFR
3 regulation of ERK1 and ERK2 cascade GO:0070372 9.37 ERBB2 EGFR
4 positive regulation of cell proliferation GO:0008284 9.35 VEGFD PROX1 ERBB2 EGFR CSF3
5 negative regulation of ERBB signaling pathway GO:1901185 9.16 ERBB2 EGFR
6 positive regulation of protein kinase B signaling GO:0051897 8.92 ESR1 ERBB2 EGFR CSF3

Molecular functions related to Inflammatory Breast Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.63 VEGFD PGR ESR1 ERBB2 EGFR CDH1
2 enzyme binding GO:0019899 9.56 PGR ESR1 EGFR CSF3
3 growth factor activity GO:0008083 9.5 VEGFD CSF3 CCN6
4 ATPase binding GO:0051117 9.13 PGR ESR1 EGFR
5 nitric-oxide synthase regulator activity GO:0030235 8.62 ESR1 EGFR

Sources for Inflammatory Breast Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....